Escara-Wilke J - Search Results

1

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.

Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET. Wallner L, et al. Cancer Res. 2006 Mar 15;66(6):3087-95. doi: 10.1158/0008-5472.CAN-05-3447. Cancer Res. 2006. PMID: 16540658

2

Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression.

Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W. Kryczek I, et al. J Immunol. 2007 Aug 1;179(3):1423-6. doi: 10.4049/jimmunol.179.3.1423. J Immunol. 2007. PMID: 17641006

3

New trends in the treatment of bone metastasis.

Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS, Keller J. Keller ET, et al. J Cell Biochem. 2007 Dec 1;102(5):1095-102. doi: 10.1002/jcb.21540. J Cell Biochem. 2007. PMID: 17955492 Free article. Review.

4

RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.

Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET. Ignatoski KM, et al. Prostate. 2008 Jun 1;68(8):820-9. doi: 10.1002/pros.20744. Prostate. 2008. PMID: 18324676 Free PMC article.

5

Heat stress-induced heat shock protein 70 expression is dependent on ERK activation in zebrafish (Danio rerio) cells.

Keller JM, Escara-Wilke JF, Keller ET. Keller JM, et al. Comp Biochem Physiol A Mol Integr Physiol. 2008 Jul;150(3):307-14. doi: 10.1016/j.cbpa.2008.03.021. Epub 2008 Apr 7. Comp Biochem Physiol A Mol Integr Physiol. 2008. PMID: 18467140 Free PMC article.

6

Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.

Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Dai J, et al. Cancer Res. 2008 Jul 15;68(14):5785-94. doi: 10.1158/0008-5472.CAN-07-6541. Cancer Res. 2008. PMID: 18632632 Free PMC article.

7

Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.

Ignatoski KM, Friedman J, Escara-Wilke J, Zhang X, Daignault S, Dunn RL, Smith DC, Keller ET. Ignatoski KM, et al. J Interferon Cytokine Res. 2009 Feb;29(2):105-12. doi: 10.1089/jir.2008.0024. J Interferon Cytokine Res. 2009. PMID: 19014338 Free PMC article. Clinical Trial.

8

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Bradley DA, et al. Invest New Drugs. 2011 Dec;29(6):1432-40. doi: 10.1007/s10637-010-9420-8. Epub 2010 Mar 25. Invest New Drugs. 2011. PMID: 20336348 Free PMC article. Clinical Trial.

9

ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines.

Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, Keller ET. Yu C, et al. In Vivo. 2011 Jan-Feb;25(1):69-76. In Vivo. 2011. PMID: 21282737

10

Raf kinase inhibitor protein (RKIP) in cancer.

Escara-Wilke J, Yeung K, Keller ET. Escara-Wilke J, et al. Cancer Metastasis Rev. 2012 Dec;31(3-4):615-20. doi: 10.1007/s10555-012-9365-9. Cancer Metastasis Rev. 2012. PMID: 22684368 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters